Halozyme Therapeutics (NASDAQ:HALO) reported non-GAAP earnings per share (EPS) of $1.54, beating non-GAAP estimates by $0.30 and growing 69% year over year (non-GAAP). Revenue (GAAP) was $325.7 ...

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +25.20% and +13.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

SAN DIEGO (AP) — SAN DIEGO (AP) — Halozyme Therapeutics Inc. (HALO) on Tuesday reported second-quarter net income of $165.2 million. On a per-share basis, the San Diego-based company said it had ...

The company raised its full-year 2025 guidance, now expecting earnings per share of $6.00-$6.40, well above the consensus estimate of $5.40. Halozyme also increased its revenue forecast to $1.27-1.35 ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the second quarter ended June 30, 2025, provided an update on its recent ...

Analysts anticipate Exact Sciences to report an earnings per share (EPS) of $0.02. Anticipation surrounds Exact Sciences's ...

Analysts expect Halozyme Therapeutics to report an earnings per share (EPS) of $1.20. Anticipation surrounds Halozyme ...

Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's earnings results every quarter. The ...

The new rating shows the stock is outpacing 96% of all stocks when it comes to the most important stock-picking criteria. The ...

Highlights,A key director reduced their stake in Halozyme Therapeutics during the past year,The transaction was executed ...

DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement in early intervention for multiple myeloma ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.